Paradigm Therapeutics forms new subsidiary in Singapore
Paradigm Therapeutics, the UK drug discovery company located in Cambridge, has formed a wholly owned Singapore subsidiary based in the Biopolis, a new state of the art facility tipped to be a world-class biomedical research and development hub in Asia.
Paradigm Therapeutics, the UK drug discovery company located in Cambridge, has formed a wholly owned Singapore subsidiary based in the Biopolis, a new state of the art facility tipped to be a world-class biomedical research and development hub in Asia.
Paradigm Therapeutics Singapore Pte Limited will capitalise on the rapid growth of biomedical research in Singapore and establish a research and development base for its genomics-driven drug target validation activities in the Biopolis.
Dr Ian Gray has been appointed as head of research at the new company. He joins Paradigm from GlaxoSmithKline Pharmaceuticals, where he was manager, molecular genetics in GSK's UK genetics research division.
'This expansion into the biomedical sciences hub of Singapore will significantly increase our capacity to validate novel drug targets from the human genome,' said Dr Mark Carlton, ceo and co-founder of Paradigm Therapeutics. 'The Singapore environment is highly dynamic and offers an excellent base to reach Asia-Pacific markets.'
Dr Samuel Aparicio (University of Cambridge Department of Oncology and visiting professor at the Institute of Molecular and Cell Biology, Singapore), cso and co-founder of Paradigm Therapeutics, added: 'The strong skills base for biomedical researchers in Singapore together with expansion in biomedical research facilities offer the prospect of rapid growth in our science base.'